



GELSYN³

3 injection hyaluronic acid treatment

The Next Generation Hyaluronic Acid for You and Your Patients

Innovation from Process to Patient

Hyaluronic Acid (HA) Therapy for the Next Generation




- Box includes:
- 1 - 2.0 mL syringe
 - 1 - 21 gauge needle



GELSYN-3

A Strong Therapeutic Choice

- *Clinically equivalent to Synvisc¹*
 - *Well-tolerated, 3 injection regimen offers long-lasting osteoarthritis knee pain relief (6 months)¹*
 - *May delay the need for Total Knee Replacement²*
 - *Less treatment-related events compared to Synvisc in a clinical study¹*
 - *Biofermentation based formulation removes risk of avian based allergies and sensitivities³*
- 

Results at 26 weeks

Effective Viscosupplement Performance for Improved Outcomes¹



GELSYN-3 performs as well as Synvisc in terms of effectiveness and safety, providing patients with long-lasting, clinically relevant pain relief.



GELSYN-3
32.5 mm
reduction

in pain scores
at 26 weeks

93-97%

of patients and investigators
scored global tolerability
as **good** or **very good**

Results at 12 weeks

At week 12, GELSYN-3 patients:

- demonstrated a decrease in Lequesne pain scores compared to Synvisc
- showed a **37% reduction** in pain medication use



Trusted HA Therapy With Long-Term Benefits

➤ GELSYN-3 offers a good safety profile.

In a clinical trial fewer treatment-related adverse events were reported compared to Synvisc.¹

Synvisc Group



Treatment Related
Adverse Events

-vs-

GELSYN-3 Group



Treatment Related
Adverse Event

➤ Well-tolerated, 3 injection regimen provides long-lasting positive outcomes (approximately 6 months/ 26 weeks)¹

GELSYN-3[™]
3 injection hyaluronic acid treatment



1930's

HA discovery
from bovine extract

**1940's
& 1950's**

Extraction from
animal sources

**1960's
& 1970's**

First uses
in medicine

**1990's
& 2000's**

Avian-derived
HA to market

TODAY

Advanced
Biofermentation
Technology

GELSYN-3 utilizes biofermentation technology for the next generation

GELSYN-3 is committed to advancing the benefits of HA therapy

- *Fully automated production methods virtually eliminates contamination and human error³*
- *Low level of impurities, including proteins and bacterial endotoxins⁴*
- *GELSYN-3 is a biofermentation based formulation that may remove the risk of avian allergies and sensitivities*
- *Bacterial fermentation of Streptococcus groups A and C is safe and non-genetically modified (non-GMO)^{3,5}*



The Next Generation of Hyaluronic Acid Therapy is Here

Prescribe GELSYN-3 3 injection hyaluronic acid treatment

Nearly 5 million GELSYN-3 syringes sold in 19 countries since 2002^{5*}

- *Effective and safe clinical performance, equivalent to Synvisc¹*
- *Well tolerated, 3 injection regimen delivers long-lasting osteoarthritis knee pain relief (6 months)¹*
- *May delay the need for Total Knee Replacement²*
- *Biofermentation based formulation removes risk of avian based allergies and sensitivities³*



**GELSYN-3 has a
dedicated J-code
of J-7328**

Visit us at **GELSYN3.com** or call **800-836-4080** to learn more.

References: 1. Pavelka K, Uebelhart D. Efficacy evaluation of highly purified intra-articular hyaluronic acid (Sinovial) vs. hylan G-F20 (Synvisc) in the treatment of symptomatic knee osteoarthritis. A double-blind, controlled, randomized, parallel-group non-inferiority study. *Osteoarthritis Cartilage*. 2011 Nov;19(11):1294-300. doi: 10.1016/j.joca.2011.07.016. Epub 2011 Aug 16. 2. Altman R, Lim S, Steen RG, Dasa V. (2015) Hyaluronic Acid Injections Are Associated with Delay of Total Knee Replacement Surgery in Patients with Knee Osteoarthritis: Evidence from a Large U.S. Health Claims Database. *PLoS ONE* 10(12): e0145776. doi:10.1371/journal.pone.0145776. 3. <http://www.ibsa-international.com/innovation/> (Accessed May 2016). 4. http://www.htl-bio.com/products/304/safety_by_design.php (Accessed May 2016). 5. RPT-000529 Data on File DOF Sinovial Sales Data.

Summary of Indications for Use: GELSYN-3 is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen). Do not administer to patients with known hypersensitivity (allergy) to sodium hyaluronate preparations. Do not inject GELSYN-3 into the knees of patients having knee joint infections or skin diseases or infections in the area of the injection site.

GELSYN-3 is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site. Full prescribing information can be found in product labeling, at www.GELSYN3.com or by contacting customer service at 800-836-4080.

*Sinovial[®] is branded as GELSYN-3 for the US Market.

¹While not specifically studied in Altman et. al analysis², GelSyn-3 belongs to the HA class, and has been found to perform similar to Synvisc¹, which was included in the HA brands analyzed.

Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
GELSYN-3 is a trademark of Bioventus LLC.